[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX350875B - Formas de dosificacion farmaceutica de liberacion controlada. - Google Patents

Formas de dosificacion farmaceutica de liberacion controlada.

Info

Publication number
MX350875B
MX350875B MX2013010987A MX2013010987A MX350875B MX 350875 B MX350875 B MX 350875B MX 2013010987 A MX2013010987 A MX 2013010987A MX 2013010987 A MX2013010987 A MX 2013010987A MX 350875 B MX350875 B MX 350875B
Authority
MX
Mexico
Prior art keywords
dosage forms
controlled release
pharmaceutical dosage
release pharmaceutical
layer
Prior art date
Application number
MX2013010987A
Other languages
English (en)
Other versions
MX2013010987A (es
Inventor
Haiyong Hugh Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MX2013010987A publication Critical patent/MX2013010987A/es
Publication of MX350875B publication Critical patent/MX350875B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a formas de dosificación farmacéuticas multicapa, por ejemplo a una forma de dosificación resistente a la manipulación que comprende una primera capa que comprende un agente activo y una segunda capa que no comprende dicho agente activo y procesos de elaboración, usos, y métodos de tratamiento del mismo que proporciona liberación esencialmente de orden cero.
MX2013010987A 2011-03-25 2012-03-22 Formas de dosificacion farmaceutica de liberacion controlada. MX350875B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467824P 2011-03-25 2011-03-25
PCT/IB2012/000595 WO2012131463A2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms

Publications (2)

Publication Number Publication Date
MX2013010987A MX2013010987A (es) 2014-10-13
MX350875B true MX350875B (es) 2017-09-19

Family

ID=46018006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010987A MX350875B (es) 2011-03-25 2012-03-22 Formas de dosificacion farmaceutica de liberacion controlada.

Country Status (24)

Country Link
US (1) US20140056979A1 (es)
EP (1) EP2688556B1 (es)
JP (1) JP5964940B2 (es)
KR (1) KR101619579B1 (es)
CN (1) CN103547259A (es)
AU (1) AU2012235878B2 (es)
BR (1) BR112013024585A8 (es)
CA (1) CA2831218C (es)
CY (1) CY1116579T1 (es)
DK (1) DK2688556T3 (es)
ES (1) ES2544735T3 (es)
HR (1) HRP20150835T1 (es)
HU (1) HUE026981T2 (es)
IL (1) IL228441B (es)
ME (1) ME02189B (es)
MX (1) MX350875B (es)
PH (1) PH12013501994A1 (es)
PL (1) PL2688556T3 (es)
PT (1) PT2688556E (es)
RS (1) RS54152B1 (es)
SI (1) SI2688556T1 (es)
SM (1) SMT201500209B (es)
WO (1) WO2012131463A2 (es)
ZA (1) ZA201307862B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1227798A4 (en) 1999-10-29 2004-06-30 Euro Celtique Sa HYDRCODON FORMULATIONS WITH CONTROLLED RELEASE
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
PE20181177A1 (es) 2010-12-22 2018-07-20 Purdue Pharma Lp Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
HK1207586A1 (en) 2012-04-17 2016-02-05 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
BR112019027889A2 (pt) 2017-06-30 2020-07-07 Purdue Pharma L.P. método de tratamento e formas de dosagem do mesmo
CA3073570A1 (en) * 2017-08-31 2019-03-07 Purdue Pharma L.P. Opioid oral extended release formulations comprising an anionic surfactant and polyethylene oxide
JP7377202B2 (ja) 2017-12-20 2023-11-09 パーデュー、ファーマ、リミテッド、パートナーシップ 乱用抑止硫酸モルヒネ剤形

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007907B1 (ko) * 1992-09-01 1995-07-21 동국제약 주식회사 치주질환 치료용 막형 국소약물송달제제
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
EP1251832B1 (en) * 2000-02-04 2006-09-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
KR101167465B1 (ko) * 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
FI1765303T4 (fi) * 2004-07-01 2023-01-31 Väärinkäytöltä suojattu oraalinen tabletti
US7434308B2 (en) * 2004-09-02 2008-10-14 International Business Machines Corporation Cooling of substrate using interposer channels
US20060257484A1 (en) * 2005-04-19 2006-11-16 Hwang Stephen S Combination of tramadol and substances that comprise gabapentin
US20100059285A1 (en) * 2006-05-17 2010-03-11 Carlstroem Bo Top hammer rock-drilling tool, a drill rod coupling sleeve
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8241993B2 (en) * 2007-07-13 2012-08-14 Marvell World Trade Ltd. Method for shallow trench isolation
CN102105136B (zh) * 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
CN101933907A (zh) * 2009-06-30 2011-01-05 北京天衡药物研究院 新型骨架缓释片及其制备方法

Also Published As

Publication number Publication date
CN103547259A (zh) 2014-01-29
ZA201307862B (en) 2014-06-25
AU2012235878A1 (en) 2013-05-02
KR20130135973A (ko) 2013-12-11
ES2544735T3 (es) 2015-09-03
JP5964940B2 (ja) 2016-08-03
NZ616600A (en) 2015-07-31
SMT201500209B (it) 2015-10-30
MX2013010987A (es) 2014-10-13
IL228441B (en) 2019-05-30
US20140056979A1 (en) 2014-02-27
DK2688556T3 (en) 2015-08-03
PT2688556E (pt) 2015-09-11
AU2012235878B2 (en) 2015-10-15
RS54152B1 (en) 2015-12-31
CA2831218C (en) 2017-01-17
EP2688556A2 (en) 2014-01-29
BR112013024585A8 (pt) 2018-01-09
HRP20150835T1 (hr) 2015-09-11
WO2012131463A3 (en) 2012-11-29
CA2831218A1 (en) 2012-10-04
HUE026981T2 (en) 2016-08-29
PH12013501994A1 (en) 2013-12-02
EP2688556B1 (en) 2015-05-06
WO2012131463A2 (en) 2012-10-04
KR101619579B1 (ko) 2016-05-10
PL2688556T3 (pl) 2015-10-30
IL228441A0 (en) 2013-12-31
SI2688556T1 (sl) 2015-09-30
ME02189B (me) 2016-02-20
JP2014510094A (ja) 2014-04-24
CY1116579T1 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
PH12014502462A1 (en) Complement pathway modulators and uses thereof
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2014002058A3 (en) Complement pathway modulators and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
WO2014009833A3 (en) Complement pathway modulators and uses thereof
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
JO2858B1 (en) Pharmaceutical dosage images
MX359288B (es) Forma iv del clorhidrato de ivabradina.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MY176793A (en) Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel
IN2014MN02236A (es)
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
PH12013502325A1 (en) Drug delivery system
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX360235B (es) Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo.
MX2016006738A (es) Procedimiento para producir material particulado inorganico.
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
JO3641B1 (ar) تركيبة مضادات الفيروسات القهقرية
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.

Legal Events

Date Code Title Description
FG Grant or registration